SMAD4, activated by the TCR-triggered MEK/ERK signaling pathway, critically regulates CD8+ T cell cytotoxic function

Sci Adv. 2022 Jul 29;8(30):eabo4577. doi: 10.1126/sciadv.abo4577. Epub 2022 Jul 27.

Abstract

Transforming growth factor-β is well known to restrain cytotoxic T cell responses to maintain self-tolerance and to promote tumor immune evasion. In this study, we have investigated the role of SMAD4, a core component in the TGF-β signaling pathway, in CD8+ T cells. Unexpectedly, we found that SMAD4 was critical in promoting CD8+ T cell function in both tumor and infection models. SMAD4-mediated transcriptional regulation of CD8+ T cell activation and cytotoxicity was dependent on the T cell receptor (TCR) but not TGF-β signaling pathway. Following TCR activation, SMAD4 translocated into the nucleus, up-regulated genes encoding TCR signaling components and cytotoxic molecules in CD8+ T cells and thus reinforced T cell function. Biochemically, SMAD4 was directly phosphorylated by ERK at Ser367 residue following TCR activation. Our study thus demonstrates a critical yet unexpected role of SMAD4 in promoting CD8+ T cell-mediated cytotoxic immunity.

MeSH terms

  • CD8-Positive T-Lymphocytes*
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Receptors, Antigen, T-Cell
  • Signal Transduction*
  • Transforming Growth Factor beta / metabolism

Substances

  • Receptors, Antigen, T-Cell
  • Transforming Growth Factor beta
  • Mitogen-Activated Protein Kinase Kinases